Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyrotropin | 3 | 2022 | 49 | 1.540 |
Why?
|
| Hypothyroidism | 2 | 2022 | 24 | 1.500 |
Why?
|
| Thyroxine | 3 | 2022 | 62 | 0.940 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2022 | 6 | 0.820 |
Why?
|
| Parathyroid Glands | 1 | 2022 | 22 | 0.810 |
Why?
|
| Research | 1 | 2022 | 214 | 0.740 |
Why?
|
| Learning | 1 | 2022 | 186 | 0.710 |
Why?
|
| Sports Medicine | 1 | 2019 | 22 | 0.680 |
Why?
|
| Athletes | 1 | 2019 | 40 | 0.680 |
Why?
|
| Sleep Aids, Pharmaceutical | 1 | 2019 | 6 | 0.680 |
Why?
|
| Prescription Drugs | 1 | 2019 | 71 | 0.640 |
Why?
|
| Analgesics | 1 | 2019 | 118 | 0.620 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 91 | 0.610 |
Why?
|
| Osteoporosis | 1 | 2018 | 88 | 0.600 |
Why?
|
| Family Practice | 1 | 2020 | 312 | 0.580 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 498 | 0.510 |
Why?
|
| Group Processes | 1 | 2014 | 42 | 0.480 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 694 | 0.450 |
Why?
|
| Anxiety Disorders | 1 | 2016 | 426 | 0.430 |
Why?
|
| Health Occupations | 1 | 2011 | 28 | 0.390 |
Why?
|
| Thyroid Neoplasms | 2 | 2022 | 68 | 0.380 |
Why?
|
| Drug Interactions | 1 | 2011 | 289 | 0.380 |
Why?
|
| Students, Pharmacy | 1 | 2011 | 79 | 0.370 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 504 | 0.350 |
Why?
|
| Education, Pharmacy | 1 | 2011 | 102 | 0.350 |
Why?
|
| Chronic Disease | 1 | 2014 | 1330 | 0.350 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2016 | 1085 | 0.330 |
Why?
|
| Humans | 18 | 2022 | 68618 | 0.300 |
Why?
|
| Calcium | 2 | 2022 | 929 | 0.270 |
Why?
|
| Vitamin D | 2 | 2022 | 516 | 0.260 |
Why?
|
| Endocrine System Diseases | 3 | 2018 | 11 | 0.240 |
Why?
|
| Anti-Bacterial Agents | 2 | 2021 | 1026 | 0.230 |
Why?
|
| Thyroid Function Tests | 1 | 2022 | 21 | 0.200 |
Why?
|
| Hyperthyroidism | 1 | 2022 | 13 | 0.200 |
Why?
|
| Hormone Replacement Therapy | 2 | 2018 | 20 | 0.200 |
Why?
|
| Thyroid Nodule | 1 | 2022 | 15 | 0.200 |
Why?
|
| Parathyroidectomy | 1 | 2022 | 45 | 0.200 |
Why?
|
| Thyroid Gland | 1 | 2022 | 67 | 0.200 |
Why?
|
| Diabetic Foot | 1 | 2021 | 33 | 0.190 |
Why?
|
| Cysts | 1 | 2022 | 70 | 0.190 |
Why?
|
| Parathyroid Hormone | 1 | 2022 | 117 | 0.190 |
Why?
|
| Sleep Hygiene | 1 | 2019 | 3 | 0.170 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2019 | 92 | 0.170 |
Why?
|
| Telomere Homeostasis | 1 | 2018 | 6 | 0.160 |
Why?
|
| Insulin | 2 | 2019 | 619 | 0.160 |
Why?
|
| Female | 7 | 2022 | 38074 | 0.160 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2018 | 26 | 0.160 |
Why?
|
| Menopause | 1 | 2018 | 47 | 0.160 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 567 | 0.160 |
Why?
|
| Healthy Lifestyle | 1 | 2018 | 21 | 0.160 |
Why?
|
| Incidental Findings | 1 | 2018 | 42 | 0.160 |
Why?
|
| Diphosphonates | 1 | 2018 | 39 | 0.160 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2019 | 257 | 0.160 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 186 | 0.150 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 1851 | 0.150 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 240 | 0.150 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 951 | 0.140 |
Why?
|
| Exercise Therapy | 1 | 2018 | 183 | 0.140 |
Why?
|
| Antioxidants | 1 | 2018 | 304 | 0.140 |
Why?
|
| Behavioral Symptoms | 1 | 2016 | 32 | 0.130 |
Why?
|
| Pregnancy | 1 | 2022 | 2334 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1745 | 0.130 |
Why?
|
| Drug Utilization Review | 1 | 2016 | 19 | 0.130 |
Why?
|
| Dietary Supplements | 1 | 2018 | 332 | 0.130 |
Why?
|
| Asthma | 1 | 2019 | 345 | 0.130 |
Why?
|
| Anti-Anxiety Agents | 1 | 2016 | 107 | 0.130 |
Why?
|
| Patient Selection | 1 | 2019 | 592 | 0.130 |
Why?
|
| Prognosis | 1 | 2020 | 2093 | 0.120 |
Why?
|
| Antidepressive Agents | 1 | 2016 | 216 | 0.120 |
Why?
|
| Antipsychotic Agents | 1 | 2016 | 247 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 362 | 0.110 |
Why?
|
| Aging | 1 | 2018 | 911 | 0.100 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 378 | 0.100 |
Why?
|
| Aged | 4 | 2018 | 14862 | 0.090 |
Why?
|
| Mental Disorders | 1 | 2016 | 659 | 0.090 |
Why?
|
| Primary Health Care | 1 | 2016 | 703 | 0.090 |
Why?
|
| Hypertension | 1 | 2019 | 1535 | 0.090 |
Why?
|
| Male | 5 | 2018 | 37321 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2020 | 7029 | 0.080 |
Why?
|
| Iodine Radioisotopes | 1 | 2022 | 119 | 0.050 |
Why?
|
| Shoes | 1 | 2021 | 8 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2022 | 76 | 0.050 |
Why?
|
| Adult | 1 | 2020 | 21403 | 0.050 |
Why?
|
| Debridement | 1 | 2021 | 55 | 0.050 |
Why?
|
| Bandages | 1 | 2021 | 33 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2022 | 453 | 0.040 |
Why?
|
| Metanephrine | 1 | 2018 | 11 | 0.040 |
Why?
|
| Hot Flashes | 1 | 2018 | 8 | 0.040 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2018 | 11 | 0.040 |
Why?
|
| Adrenal Glands | 1 | 2018 | 46 | 0.040 |
Why?
|
| Endocrine System | 1 | 2018 | 11 | 0.040 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2018 | 32 | 0.040 |
Why?
|
| Aldosterone | 1 | 2018 | 51 | 0.040 |
Why?
|
| Catecholamines | 1 | 2018 | 73 | 0.040 |
Why?
|
| Clonidine | 1 | 2018 | 66 | 0.040 |
Why?
|
| Renin | 1 | 2018 | 96 | 0.040 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2018 | 128 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2018 | 150 | 0.040 |
Why?
|
| Biopsy | 1 | 2018 | 540 | 0.030 |
Why?
|
| Colesevelam Hydrochloride | 1 | 2016 | 6 | 0.030 |
Why?
|
| Anticholesteremic Agents | 1 | 2016 | 49 | 0.030 |
Why?
|
| Risk Factors | 1 | 2021 | 5731 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 2223 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 20881 | 0.010 |
Why?
|
| Middle Aged | 1 | 2018 | 21147 | 0.010 |
Why?
|